Effect of spironolactone and vitamin e on serum metabolic parameters and insulin resistance in patients with nonalcoholic fatty liver disease

JRAAS - Journal of the Renin-Angiotensin-Aldosterone System

Volumn 12, Issue 4, 2011, Pages 498-503

  Polyzos, Stergios A ^a   Kountouras, Jannis ^a   Zafeiriadou, Efthimia ^b   Patsiaoura, Kalliopi ^b   Katsiki, Evangelia ^b   Deretzi, Georgia ^c   Zavos, Christos ^a   Tsarouchas, Georgios ^a   Rakitzi, Pantelitsa ^b   Slavakis, Aristidis ^b  

^a ARISTOTLE UNIVERSITY OF THESSALONIKI   (Greece)

^b Ippokration Hospital   (Greece)

^c PAPAGEORGIOU GENERAL HOSPITAL   (Greece)

Author keywords

Insulin resistance; metabolic syndrome; nonalcoholic fatty liver disease; nonalcoholic steatohepatitis; spironolactone; vitamin E

Indexed keywords

ALANINE AMINOTRANSFERASE; ALPHA TOCOPHEROL; ASPARTATE AMINOTRANSFERASE; CHOLESTEROL; GAMMA GLUTAMYLTRANSFERASE; GLUCOSE; HIGH DENSITY LIPOPROTEIN; INSULIN; LIPID; POTASSIUM; SODIUM; SPIRONOLACTONE; TRIACYLGLYCEROL;

ADULT; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ARTICLE; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; CHOLESTEROL BLOOD LEVEL; CLINICAL ARTICLE; CLINICAL ASSESSMENT TOOL; CONTROLLED STUDY; FEMALE; GAMMA GLUTAMYL TRANSFERASE BLOOD LEVEL; GLUCOSE BLOOD LEVEL; HOMEOSTATIC MODEL ASSESSMENT INSULIN RESISTANCE; HUMAN; INSULIN BLOOD LEVEL; INSULIN RESISTANCE; LIPID BLOOD LEVEL; LIVER BIOPSY; MALE; NONALCOHOLIC FATTY LIVER; POTASSIUM BLOOD LEVEL; QUANTITATIVE INSULIN SENSITIVISTY CHECK INDEX; RANDOMIZED CONTROLLED TRIAL; SODIUM BLOOD LEVEL; TRIACYLGLYCEROL BLOOD LEVEL;

ALDOSTERONE ANTAGONISTS; ANIMALS; FATTY LIVER; FEMALE; HUMANS; INSULIN RESISTANCE; MALE; MICE; MIDDLE AGED; SPIRONOLACTONE; VITAMIN E;

EID: 83455201680     PISSN: 14703203     EISSN: 17528976     Source Type: Journal    
DOI: 10.1177/1470320311402110     Document Type: Article

References (38)

1. Bellentani S, Marino M. Epidemiology and natural history of non-alcoholic fatty liver disease (NAFLD). Ann Hepatol. 2009 ; 8: 4-8
2. Ahmed MH, Abu EO, Byrne CD. Non-Alcoholic Fatty Liver Disease (NAFLD): New challenge for general practitioners and important burden for health authorities?. Prim Care Diabetes. 2010 ; 4: 129-137
3. Polyzos SA, Kountouras J, Zavos C. Nonalcoholic fatty liver disease: the pathogenetic roles of insulin resistance and adipocytokines. Curr Mol Med. 2009 ; 72: 299-314
4. Lewis JR, Mohanty SR. Nonalcoholic fatty liver disease: a review and update. Dig Dis Sci. 2010 ; 55: 560-578
5. Polyzos SA, Kountouras J, Zavos C, Tsiaousi E. The role of adiponectin in the pathogenesis and treatment of nonalcoholic fatty liver disease. Diabetes Obes Metab. 2010 ; 12: 365-383
6. Musso G, Gambino R, Cassader M, Pagano G. A meta-analysis of randomized trials for the treatment of nonalcoholic fatty liver disease. Hepatology. 2010 ; 52: 79-104
7. Sanyal AJ, Chalasani N, Kowdley KV, et al. Pioglitazone, vitamin E, or placebo for nonalcoholic steatohepatitis. N Engl J Med. 2010 ; 362: 1675-1685
8. Athyros VG, Mikhailidis DP, Didangelos TP, et al. Effect of multifactorial treatment on non-alcoholic fatty liver disease in metabolic syndrome: a randomised study. Curr Med Res Opin. 2006 ; 22: 873-883 (Pubitemid 43875555)
9. Filippatos TD, Elisaf MS. Combination drug treatment in patients with non-alcoholic fatty liver disease. World J Hepatol. 2010 ; 2: 139-142
10. Hirose A, Ono M, Saibara T, et al. Angiotensin II type 1 receptor blocker inhibits fibrosis in rat nonalcoholic steatohepatitis. Hepatology. 2007 ; 45: 1375-1381 (Pubitemid 46918321)
11. Giacchetti G, Sechi LA, Rilli S, Carey RM. The renin-angiotensin- aldosterone system, glucose metabolism and diabetes. Trends Endocrinol Metab. 2005 ; 16: 120-126 (Pubitemid 40432462)
12. Bansal S, Lindenfeld J, Schrier RW. Sodium retention in heart failure and cirrhosis: potential role of natriuretic doses of mineralocorticoid antagonist?. Circ Heart Fail. 2009 ; 2: 370-376
13. Wada T, Kenmochi H, Miyashita Y, et al. Spironolactone improves glucose and lipid metabolism by ameliorating hepatic steatosis and inflammation and suppressing enhanced gluconeogenesis induced by high-fat and high-fructose diet. Endocrinology. 2010 ; 151: 2040-2049
14. Kleiner DE, Brunt EM, Van Natta M, et al. Design and validation of a histological scoring system for nonalcoholic fatty liver disease. Hepatology. 2005 ; 41: 1313-1321 (Pubitemid 40770284)
15. Chalasani NP, Sanyal AJ, Kowdley KV, et al. Pioglitazone versus vitamin E versus placebo for the treatment of non-diabetic patients with non-alcoholic steatohepatitis: PIVENS trial design. Contemp Clin Trials. 2009 ; 30: 88-96
16. Matthews DR, Hosker JP, Rudenski AS, Naylor BA, Treacher DF, Turner RC. Homeostasis model assessment: insulin resistance and beta-cell function from fasting plasma glucose and insulin concentrations in man. Diabetologia. 1985 ; 28: 412-419 (Pubitemid 15018832)
17. Katz A, Nambi SS, Mather K, et al. Quantitative insulin sensitivity check index: a simple, accurate method for assessing insulin sensitivity in humans. J Clin Endocrinol Metab. 2000 ; 85: 2402-2410 (Pubitemid 32269192)
18. Struthers AD, MacDonald TM. Review of aldosterone- and angiotensin II-induced target organ damage and prevention. Cardiovasc Res. 2004 ; 61: 663-670 (Pubitemid 38249465)
19. Oyamada N, Sone M, Miyashita K, et al. The role of mineralocorticoid receptor expression in brain remodeling after cerebral ischemia. Endocrinology. 2008 ; 149: 3764-3777
20. Dorrance AM. Stroke therapy: is spironolactone the Holy Grail?. Endocrinology. 2008 ; 149: 3761-3763
21. Fujisawa G, Muto S, Okada K, Kusano E, Ishibashi S. Mineralocorticoid receptor antagonist spironolactone prevents pig serum-induced hepatic fibrosis in rats. Transl Res. 2006 ; 148: 149-156 (Pubitemid 44287632)
22. Wada T, Ohshima S, Fujisawa E, Koya D, Tsuneki H, Sasaoka T. Aldosterone inhibits insulin-induced glucose uptake by degradation of insulin receptor substrate (IRS) 1 and IRS2 via a reactive oxygen species-mediated pathway in 3T3-L1 adipocytes. Endocrinology. 2009 ; 150: 1662-1669
23. Yamashita R, Kikuchi T, Mori Y, et al. Aldosterone stimulates gene expression of hepatic gluconeogenic enzymes through the glucocorticoid receptor in a manner independent of the protein kinase B cascade. Endocr J. 2004 ; 51: 243-251 (Pubitemid 38657562)
24. Guo C, Ricchiuti V, Lian BQ, et al. Mineralocorticoid receptor blockade reverses obesity-related changes in expression of adiponectin, peroxisome proliferator-activated receptor-gamma, and proinflammatory adipokines. Circulation. 2008 ; 117: 2253-2261
25. Hirata A, Maeda N, Hiuge A, et al. Blockade of mineralocorticoid receptor reverses adipocyte dysfunction and insulin resistance in obese mice. Cardiovasc Res. 2009 ; 84: 164-172
26. Noguchi R, Yoshiji H, Ikenaka Y, et al. Selective aldosterone blocker ameliorates the progression of non-alcoholic steatohepatitis in rats. Int J Mol Med. 2010 ; 26: 407-413
27. Catena C, Lapenna R, Baroselli S, et al. Insulin sensitivity in patients with primary aldosteronism: a follow-up study. J Clin Endocrinol Metab. 2006 ; 91: 3457-3463 (Pubitemid 44402119)
28. Fallo F, Dalla PA, Tecchio M, et al. Nonalcoholic fatty liver disease in primary aldosteronism: a pilot study. Am J Hypertens. 2010 ; 23: 2-5
29. Kebapcilar L, Taner CE, Kebapcilar AG, Alacacioglu A, Sari I. Comparison of four different treatment regimens on coagulation parameters, hormonal and metabolic changes in women with polycystic ovary syndrome. Arch Gynecol Obstet. 2009 ;:
30. Zulian E, Sartorato P, Benedini S, et al. Spironolactone in the treatment of polycystic ovary syndrome: effects on clinical features, insulin sensitivity and lipid profile. J Endocrinol Invest. 2005 ; 28: 49-53 (Pubitemid 43162809)
31. Nakhjavani M, Hamidi S, Esteghamati A, Abbasi M, Nosratian-Jahromi S, Pasalar P. Short term effects of spironolactone on blood lipid profile: a 3-month study on a cohort of young women with hirsutism. Br J Clin Pharmacol. 2009 ; 68: 634-637
32. Yutaka M, Mifune M, Kubota E, Itoh H, Saito I. Comparison of effects of low dose of spironolactone and a thiazide diuretic in patients with hypertension treated with an angiotensin-converting enzyme inhibitor or an angiotensin type 1 receptor blocker. Clin Exp Hypertens. 2009 ; 31: 648-656
33. Ustundag A, Tugrul A, Ustundag S, Sut N, Demirkan B. The effects of spironolactone on nephron function in patients with diabetic nephropathy. Ren Fail. 2008 ; 30: 982-991
34. Davidson MB, Wong A, Hamrahian AH, Stevens M, Siraj ES. Effect of spironolactone therapy on albuminuria in patients with type 2 diabetes treated with angiotensin- converting enzyme inhibitors. Endocr Pract. 2008 ; 14: 985-992
35. Matsumoto S, Takebayashi K, Aso Y. The effect of spironolactone on circulating adipocytokines in patients with type 2 diabetes mellitus complicated by diabetic nephropathy. Metabolism. 2006 ; 55: 1645-1652 (Pubitemid 44827131)
36. Kourounakis PN, Rekka E. Effect of spironolactone on dimethyl mercury toxicity. A possible molecular mechanism. Arzneimittelforschung. 1994 ; 44: 1150-1153
37. Mihas AA, Foster MM, Barnes S, Mihas TA, Hirschowitz BI, Spenney JG. Modification of D-galactosamine-induced liver injury in the rat by spironolactone. Pharmacology. 1979 ; 18: 235-240 (Pubitemid 9206439)
38. Skrha J, Haas T, Sindelka G, et al. Comparison of the insulin action parameters from hyperinsulinemic clamps with homeostasis model assessment and QUICKI indexes in subjects with different endocrine disorders. J Clin Endocrinol Metab. 2004 ; 89: 135-141 (Pubitemid 38183872)